Ridogrel

Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities[1][2][3].

Product Specifications

CAS Number

110140-89-1

Product Name Alternative

R 68070

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ridogrel.html

Purity

99.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2

Molecular Formula

C18H17F3N2O3

Molecular Weight

366.33

Precautions

H302, H312, H332

References & Citations

[1]De Clerck F, et al. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989;61 (1) :43-49.|[2]Di Perri T, et al. Ridogrel, una nuova molecula antiaggregante piastrinica a doppio meccanismo d'azione. Profilo farmacologico e clinico [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991;82 (10) :533-540.|[3]Carty E, et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14 (6) :807-817.